Benfluorex
From Wikipedia, the free encyclopedia
 |
|
|
Benfluorex
|
|
| Systematic (IUPAC) name | |
| 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino] ethyl benzoate |
|
| Identifiers | |
| CAS number | |
| ATC code | C10 |
| PubChem | |
| Chemical data | |
| Formula | C19H20F3NO2 |
| Mol. mass | 351.363 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Benfluorex is an anorectic and hypolipidemic agent. Clinical studies have shown it may improve glycemic control and decrease insulin resistance in people with poorly controlled type 2 diabetes;[1][2] it is marketed in France as an adjuvant antidiabetic.
Benfluorex is structurally related to fenfluramine.
[edit] References
- ^ Moulin P, Andre M, Alawi H, et al (2006). "Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study". Diabetes Care 29 (3): 515–20. PMID 16505498. Free full text
- ^ Roger P, Auclair J, Drain P (1999). "Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo". J Diabetes Complications 13 (2): 62–7. PMID 10432168.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||
